By SPC News Staff
An investigational new drug that targets human papillomavirus type 16 (HPV-16) in solid tumor cancers caused by HPV shows promise, according to a session at the 2018 annual meeting of the American Society of Clinical Oncology in Chicago (abstract 3043).
T-cell receptor (TCR) therapy is a type of personalized immunotherapy designed to activate the immune system’s ability to recognize and target specific tumors. TCR therapy involves engineering a person’s own T cells